A Phase 2 interventional study of Efgartigimod in Primary Sjögren's Syndrome, sponsored by argenx. Completed at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by argenx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Efgartigimod has the potential to improve disease manifestations by the reduction of IgG autoantibodies in Sjogren's Syndrome (SjD or pSS). This open-label extension study will evaluate the long-term safety of efgartigimod in participants with SjD who have completed the treatment period of the qualifying efgartigimod study (ARGX-113-2106).
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants received efgartigimod 10 mg/kg via intravenous infusion once weekly or once every 2 weeks for up to 48 weeks in this study.
Biological: Efgartigimod
Patients receiving efgartigimod infusions
Number of Participants With TEAEs, TESAEs and TEAESIs
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. Treatment-emergent adverse events (TEAEs) were defined as AEs with onset on or after the first administration of study drug up to and including 60 days after the last study drug administration. Adverse events in the 'Infections and infestations' SOC were defined as AE of Special Interest (AESIs) because efgartigimod causes a transient reduction in total IgG levels.
Time frame: From the first dose of study drug (Day 1) up to 60 days post last study drug, approximately 56 weeks
Number of CRESS Responders at Weeks 24 and 48
A composite of relevant endpoints for Sjögren's syndrome (CRESS) measures systemic disease activity, patient-reported symptoms, tear gland function, salivary gland function, and serology, developed to assess treatment efficacy in participants with SjD. A responder is defined as improvement in at least 3 of the above mentioned 5 items of CRESS. The score ranges from 0 to 9 (higher score = worse symptoms). Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
Time frame: Weeks 24 and 48
Number of Participants With Minimal Clinically Important Improvement From Baseline in ESSDAI at Weeks 24 and 48
European alliance of associations for rheumatology (EULAR) SjD activity index (ESSDAI) measures systemic disease activity in 12 domains. The activity levels of each domain are multiplied by their respective weights to obtain the total score between 0 and 123 (higher score = worse symptoms). Minimally clinically important improvement in ESSDAI was defined as improvement of at least 3 points in ESSDAI score at Weeks 24 and 48. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106. Responder rates for the efg-efg group in the follow-up study are supplemental to those in the ARGX-113-2106 study. Because responders from the ARGX-113-2106 study (mainly in the efg-efg group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Number of Participants With Low Disease Activity in ESSDAI at Weeks 24 and 48
ESSDAI measures systemic disease activity in participants with SjD and consists of 12 domains. The activity levels of each domain (range: 0-3 points) are multiplied by their respective weights (range: 1-6 points) to obtain the total score between 0 and 123 (higher score = worse symptoms). Low disease activity in ESSDAI was defined as ESSDAI score of less than 5 at Weeks 24 and 48. Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
Time frame: Weeks 24 and 48
Number of Participants With Minimal Clinically Important Improvement From Baseline in clinESSDAI at Weeks 24 and 48
Clinical EULAR Sjögren's syndrome disease activity index (clinESSDAI) includes same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have biological domain.This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. clinESSDAI score ranges between 0-135 (higher score=worse symptoms).Minimal clinically important improvement in clinESSDAI was defined as improvement of at least 3 points in clinESSDAI score at Weeks 24 and 48.Baseline=last available non-missing measurement from parent study ARGX-113-2106.Responder rates for efgartigimod-efgartigimod group in follow-up study are supplemental to those in antecedent study (ARGX-113-2106).Because responders from ARGX-113-2106 study (mainly in efgartigimod-efgartigimod group) potentially started ARGX-113-2211 with lower baseline scores,further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Number of Participants With Low Disease Activity in clinESSDAI at Weeks 24 and 48
clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have the biological domain. This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Low disease activity in clinESSDAI was defined as clinESSDAI score of less than 5 at Weeks 24 and 48. Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
Time frame: Weeks 24 and 48
Number of Participants With Minimal Clinically Important Improvement From Baseline in ESSPRI at Weeks 24 and 48
EULAR Sjögren's syndrome patient-reported index (ESSPRI) is a questionnaire developed to measure self-reported symptoms in participants with SjD and consists of 3 items that measure dryness, fatigue, and pain. The total global score ranges from 0 to 10 by averaging the numeric scores for pain, fatigue, and dryness, with higher scores indicating more symptoms. Minimal clinically important improvement in ESSPRI was defined as decrease of 1 point or at least \>=15% at Weeks 24 and 48. Baseline was defined as the last available non-missing measurement from the study ARGX-113-2106. Responder rates for the efg-efg group in the follow-up study are supplemental to those in the ARGX-113-2106 study. Because responders from the ARGX-113-2106 study (mainly in the efg-efg group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this measure is inherently challenging due to biological and clinical limitations.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Change From Baseline in ESSDAI Score at Weeks 24 and 48
ESSDAI measures systemic disease activity in participants with SjD and consists of 12 domains: 11 organ-specific domains (cutaneous, pulmonary, renal, articular, muscular, peripheral nervous system, central nervous system, hematological, glandular, constitutional, and lymphadenopathic) and 1 biological domain reflecting B-cell activity that contributes to disease activity level scoring. The activity levels of each domain (range: 0-3 points) are multiplied by their respective weights (range: 1-6 points) to obtain the total score between 0 and 123 (higher score = worse symptoms). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Change From Baseline in clinESSDAI Score at Weeks 24 and 48
clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have the biological domain. This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Change From Baseline in ESSPRI Score at Weeks 24 and 48
ESSPRI is a questionnaire developed to measure self-reported symptoms in participants with SjD and consists of 3 items that measure dryness, fatigue, and pain. Each item includes a numeric rating scale ranging from 0: no symptoms (dryness, fatigue, or pain) to 10: maximal imaginable (dryness, fatigue, or pain). The total global score ranges from 0 to 10 and the ESSPRI is calculated by averaging the numeric scores for pain, fatigue, and dryness, with higher scores indicating more symptoms. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Number of STAR Responders at Weeks 24 and 48
Sjögren's tool for assessing response (STAR) is a composite endpoint assessing multiple clinically relevant disease features. A STAR responder is defined as a participant with a score of at least 5 points. Due to the weighting, participant must be a responder on either systemic disease activity (ESSDAI), patient-reported symptoms (ESSPRI), or both to be an overall STAR responder. The score ranges between 0 and 9 (higher score = worse outcome). Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
Time frame: Weeks 24 and 48
Percent Change From Baseline in Total IgG Levels in Serum at Week 48
Blood samples were collected at indicated timepoints to assess the total Immunoglobulin (Ig)G levels in serum. Total IgG concentrations were quantified using validated methods at a diagnostical laboratory. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.
Time frame: Baseline (Day 1) and Week 48
Percent Change From Baseline in Autoantibodies in Serum at Week 48
Blood samples were collected at indicated timepoints to assess serum autoantibodies: anti-Ro/Sjögren's syndrome-related antigen A (SS-A) and anti-La/Sjögren's syndrome-related antigen B (SS-B). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.
Time frame: Baseline (Day 1) and Week 48
Serum Concentrations of Efgartigimod
Serum samples were collected at indicated timepoints to assess the pharmacokinetic (PK) profile of efgartigimod.
Time frame: Pre-dose and post-dose at Baseline (Day 1) and pre-dose at Weeks 24 and 48
Number of Participants With ADA Against Efgartigimod Over the 48-week Treatment Period
Blood samples were collected to assess anti-drug antibodies (ADAs) against efgartigimod. Samples were analyzed by the designated laboratory in a 3-tiered approach using validated immunogenicity assays. ADA incidence included total number of participants with treatment-boosted and treatment-induced ADA. Treatment-boosted ADA was defined as participants who had a baseline positive sample and the titer value increased 4-fold or more compared to baseline. Treatment-induced ADA was defined as participants who had a baseline negative sample and at least 1 positive post-baseline samples. Number of participants with ADA incidence is presented here.
Time frame: From Baseline (Day 1) up to 48 weeks
This open-label, multicenter extension study was conducted at 11 sites in Belgium, Hungary, and Poland in adult participants with Sjögren's disease (SjD) who completed parent efgartigimod study ARGX-113-2106 (NCT05817669).
| Milestone | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Started | 17 | 7 |
| Completed | 12 | 3 |
| Not completed | 5 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Personal reason | 1 | 0 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. Treatment-emergent adverse events (TEAEs) were defined as AEs with onset on or after the first administration of study drug up to and including 60 days after the last study drug administration. Adverse events in the 'Infections and infestations' SOC were defined as AE of Special Interest (AESIs) because efgartigimod causes a transient reduction in total IgG levels.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| TEAEs | 15 | 6 |
| TESAEs | 0 | 2 |
| TEAESIs | 10 | 5 |
A composite of relevant endpoints for Sjögren's syndrome (CRESS) measures systemic disease activity, patient-reported symptoms, tear gland function, salivary gland function, and serology, developed to assess treatment efficacy in participants with SjD. A responder is defined as improvement in at least 3 of the above mentioned 5 items of CRESS. The score ranges from 0 to 9 (higher score = worse symptoms). Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 1 (0.30 to 25.01) | 4 (22.53 to 87.12) |
| Week 48 | 2 (2.13 to 32.62) | 2 (5.34 to 65.87) |
European alliance of associations for rheumatology (EULAR) SjD activity index (ESSDAI) measures systemic disease activity in 12 domains. The activity levels of each domain are multiplied by their respective weights to obtain the total score between 0 and 123 (higher score = worse symptoms). Minimally clinically important improvement in ESSDAI was defined as improvement of at least 3 points in ESSDAI score at Weeks 24 and 48. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106. Responder rates for the efg-efg group in the follow-up study are supplemental to those in the ARGX-113-2106 study. Because responders from the ARGX-113-2106 study (mainly in the efg-efg group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 3 (4.99 to 39.56) | 2 (5.34 to 65.87) |
| Week 48 | 1 (0.30 to 25.01) | 2 (5.34 to 65.87) |
ESSDAI measures systemic disease activity in participants with SjD and consists of 12 domains. The activity levels of each domain (range: 0-3 points) are multiplied by their respective weights (range: 1-6 points) to obtain the total score between 0 and 123 (higher score = worse symptoms). Low disease activity in ESSDAI was defined as ESSDAI score of less than 5 at Weeks 24 and 48. Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 9 (31.08 to 73.99) | 4 (22.53 to 87.12) |
| Week 48 | 7 (21.19 to 63.60) | 3 (12.88 to 77.47) |
Clinical EULAR Sjögren's syndrome disease activity index (clinESSDAI) includes same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have biological domain.This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. clinESSDAI score ranges between 0-135 (higher score=worse symptoms).Minimal clinically important improvement in clinESSDAI was defined as improvement of at least 3 points in clinESSDAI score at Weeks 24 and 48.Baseline=last available non-missing measurement from parent study ARGX-113-2106.Responder rates for efgartigimod-efgartigimod group in follow-up study are supplemental to those in antecedent study (ARGX-113-2106).Because responders from ARGX-113-2106 study (mainly in efgartigimod-efgartigimod group) potentially started ARGX-113-2211 with lower baseline scores,further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 2 (2.13 to 32.62) | 2 (5.34 to 65.87) |
| Week 48 | 1 (0.30 to 25.01) | 2 (5.34 to 65.87) |
clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have the biological domain. This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Low disease activity in clinESSDAI was defined as clinESSDAI score of less than 5 at Weeks 24 and 48. Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 9 (31.08 to 73.99) | 4 (22.53 to 87.12) |
| Week 48 | 7 (21.19 to 63.60) | 3 (12.88 to 77.47) |
EULAR Sjögren's syndrome patient-reported index (ESSPRI) is a questionnaire developed to measure self-reported symptoms in participants with SjD and consists of 3 items that measure dryness, fatigue, and pain. The total global score ranges from 0 to 10 by averaging the numeric scores for pain, fatigue, and dryness, with higher scores indicating more symptoms. Minimal clinically important improvement in ESSPRI was defined as decrease of 1 point or at least \>=15% at Weeks 24 and 48. Baseline was defined as the last available non-missing measurement from the study ARGX-113-2106. Responder rates for the efg-efg group in the follow-up study are supplemental to those in the ARGX-113-2106 study. Because responders from the ARGX-113-2106 study (mainly in the efg-efg group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this measure is inherently challenging due to biological and clinical limitations.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 4 (8.46 to 46.05) | 1 (0.73 to 52.07) |
| Week 48 | 4 (8.46 to 46.05) | 2 (5.34 to 65.87) |
ESSDAI measures systemic disease activity in participants with SjD and consists of 12 domains: 11 organ-specific domains (cutaneous, pulmonary, renal, articular, muscular, peripheral nervous system, central nervous system, hematological, glandular, constitutional, and lymphadenopathic) and 1 biological domain reflecting B-cell activity that contributes to disease activity level scoring. The activity levels of each domain (range: 0-3 points) are multiplied by their respective weights (range: 1-6 points) to obtain the total score between 0 and 123 (higher score = worse symptoms). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.
| score on a scale | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 0.000 (-9 to 6) | -3.000 (-5 to 0) |
| Week 48 | -1.500 (-9 to 4) | -4.000 (-5 to 2) |
clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have the biological domain. This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.
| score on a scale | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 0.000 (-11 to 4) | -3.000 (-6 to 0) |
| Week 48 | -0.500 (-11 to 4) | -4.000 (-6 to 4) |
ESSPRI is a questionnaire developed to measure self-reported symptoms in participants with SjD and consists of 3 items that measure dryness, fatigue, and pain. Each item includes a numeric rating scale ranging from 0: no symptoms (dryness, fatigue, or pain) to 10: maximal imaginable (dryness, fatigue, or pain). The total global score ranges from 0 to 10 and the ESSPRI is calculated by averaging the numeric scores for pain, fatigue, and dryness, with higher scores indicating more symptoms. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.
| score on a scale | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 0.000 (-2.00 to 0.67) | 0.167 (-5.00 to 1.00) |
| Week 48 | 0.333 (-3.33 to 2.00) | -2.000 (-5.00 to 0.00) |
Sjögren's tool for assessing response (STAR) is a composite endpoint assessing multiple clinically relevant disease features. A STAR responder is defined as a participant with a score of at least 5 points. Due to the weighting, participant must be a responder on either systemic disease activity (ESSDAI), patient-reported symptoms (ESSPRI), or both to be an overall STAR responder. The score ranges between 0 and 9 (higher score = worse outcome). Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 1 (0.30 to 25.01) | 2 (5.34 to 65.87) |
| Week 48 | 2 (2.13 to 32.62) | 3 (12.88 to 77.47) |
Blood samples were collected at indicated timepoints to assess the total Immunoglobulin (Ig)G levels in serum. Total IgG concentrations were quantified using validated methods at a diagnostical laboratory. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.
| percent change | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Percent Change From Baseline in Total IgG Levels in Serum at Week 48 | 36.266 ± 24.1776 | -37.800 ± 12.5728 |
Blood samples were collected at indicated timepoints to assess serum autoantibodies: anti-Ro/Sjögren's syndrome-related antigen A (SS-A) and anti-La/Sjögren's syndrome-related antigen B (SS-B). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.
| percent change | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| SS-A Antibody | -1.227 ± 4.2512 | -14.646 ± 25.3673 |
| SS-B Antibody | 82.487 ± 122.7263 | 0.000 ± 0.0000 |
Serum samples were collected at indicated timepoints to assess the pharmacokinetic (PK) profile of efgartigimod.
| microgram/milliliter (mcg/mL) | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Baseline, pre-dose | 14.74 ± 4.845 | — |
| Baseline, post-dose | 213.3 ± 55.19 | 215.9 ± 29.40 |
| Week 24, pre-dose | 4.428 ± 5.135 | 1.558 ± 0.2147 |
| Week 48, pre-dose | 5.725 ± 6.235 | NA ± NA |
Blood samples were collected to assess anti-drug antibodies (ADAs) against efgartigimod. Samples were analyzed by the designated laboratory in a 3-tiered approach using validated immunogenicity assays. ADA incidence included total number of participants with treatment-boosted and treatment-induced ADA. Treatment-boosted ADA was defined as participants who had a baseline positive sample and the titer value increased 4-fold or more compared to baseline. Treatment-induced ADA was defined as participants who had a baseline negative sample and at least 1 positive post-baseline samples. Number of participants with ADA incidence is presented here.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Number of Participants With ADA Against Efgartigimod Over the 48-week Treatment Period | 6 | 4 |
Collected over From the first dose of study drug (Day 1) up to 60 days post last study drug, approximately 56 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efgartigimod-Efgartigimod | 0/17 (0%) | 0/17 (0%) | 15/17 (88.2%) |
| Placebo-Efgartigimod | 0/7 (0%) | 2/7 (28.6%) | 6/7 (85.7%) |
| Event | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 0/17 | 2/7 |
| Event | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/17 | 3/7 |
| BronchitisInfections and infestations | 0/17 | 2/7 |
| ConjunctivitisInfections and infestations | 2/17 | 2/7 |
| Oral herpesInfections and infestations | 1/17 | 2/7 |
| NasopharyngitisInfections and infestations | 4/17 | 0/7 |
| COVID-19Infections and infestations | 3/17 | 0/7 |
| CystitisInfections and infestations | 3/17 | 1/7 |
| HeadacheNervous system disorders | 3/17 | 1/7 |
| Gastric antral vascular ectasiaGastrointestinal disorders | 0/17 | 1/7 |
| ToothacheGastrointestinal disorders | 0/17 | 1/7 |
Analysis was performed on full analysis set (FAS) which included all enrolled participants.
| Age, Continuous(years) | Efgartigimod-Efgartigimod | Placebo-Efgartigimod | Total |
|---|---|---|---|
| Mean | 51.2 ± 13.09 | 51.3 ± 11.48 | 51.2 ± 12.39 |
| Sex: Female, Male(Participants) | Efgartigimod-Efgartigimod | Placebo-Efgartigimod | Total |
|---|---|---|---|
| Female | 16 | 7 | 23 |
| Male | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Efgartigimod-Efgartigimod | Placebo-Efgartigimod | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 17 | 7 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Efgartigimod-Efgartigimod | Placebo-Efgartigimod | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 17 | 7 | 24 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Feb 2025, 14 months.
Results were first posted in Feb 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efgartigimod alfa